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Abstract. This paper aimed to evaluate the changes in erythrocytes, lymphocytes, biochemistry and 
microbiology of the intestinal flora in dogs treated with erythromycin. In the experiment, three groups of 
dogs were used: a group treated with the usual dose of erythromycin, one treated with double of the 
recommended dose and one control treated with physiological saline. For these groups, 12 hematological, 
11 biochemical parameters were investigated. Microbiological investigation concerned the total number of 
bacteria expressed in CFU/g feces, and sensitivity to erythromycin by diffusion method with erythromycin 
microdisks assay. The results showed no changes on erythrocyte parameters, but significant changes (p 
<0.05) on neutrophil and lymphocyte ratio in the groups treated with erythromycin. Significant changes (p 
<0.05) of alcanine phosphatase values were recorded, correlated to a reduction in CFU/g faeces directly 
proportional to the amount of erythromycin administered. Erythromycin resistance was not detected in 
strains of Staphylococcus spp, Enterococcus spp. and Proteus spp., while E. coli and Pseudomonas 
aeruginosa had a resistance of 5.26 and 50% respectively. 
 




Isolation of erythromycin was made for the first time from soil actinomycetes in the 
Philippines (Griffith and Black, 1970), purified and then used in clinical therapy by McGuire et 
al. in 1952 (McGuire et al. 1952). Later it was found that erythromycin has a wide range and can 
be used against most pathogens. Microbial antibioresistance with bacteria of the genus 
Staphylococcus is particularly common in dogs (Lloyd et al., 1996, Holm et al., 2002). Normal 
microflora microorganisms of the genus Escherichia and Enterococcus might represent a 
possibility of genes resistance transfer and can also be considered as indicators of change in 
resistance (Caprioli et al. 2000). In addition to these changes of the microbial flora, erythromycin 
may have different side effects expressed locally or general (Griffith and Black, 1970). 
This paper aimed to evaluate hematological and biochemical changes of the intestinal 
flora in dogs treated with erythromycin. 
 
MATERIALS AND METHODS 
 
Animals used in the experiment. The experiment was conducted in 2011 on 30 
clinically healthy adult dogs, the common breed, weighing between 10 and 35 kg, aged 1 to 5 
years, divided into three groups treated differently with 10% erythromycin thiocyanate solution 
or saline solution 8% administered intramuscularly every 24 hours as follows: 
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Group A - 10 dogs treated with erythromycin thiocyanate 1ml/10 kg bodyweight daily 
for 3 consecutive days; 
Group B - 10 dogs treated with erythromycin thiocyanate, 2ml/10 kg bodyweight daily 
for 3 consecutive days; 
Group C - 10 dogs treated with physiological solution 2ml/10 kg bodyweight daily for 3 
consecutive days. 
Hematology. For changes in hematological parameters were considered 12 
measurements aiming changes of both red blood cell and leukocyte parameters. The 12 
parameters investigated were representd by: hematocrit, hemoglobin, total erythrocytes, mean 
corpuscular volume (MCV), mean erythrocyte hemoglobin (MCH) and mean erythrocyte 
hemoglobin concentration in (MEHC), total leukocytes, neutrophils, eosinophils, basophils, 
lymphocytes and monocytes. Tests were performed using automated hematology analyzer and 
interpreted as reference according to Bounous and Stedman (2000), and Gylstorff I., (1983). 
Biochemistry. For changes in blood biochemical profile, 11 parameters were determined 
using serum samples. The 10 constant serum were determined by automatic dry biochemistry 
analyzer. These were: AST - aspartate aminotransferase, ALP - alkaline phosphatase, CK - creatine 
phosphokinase, CA - Calcium, Phos - phosphorus, TP - total protein, GGT - gamma-glumatil 
transferase, BUN - blood urea nitrogen, WHITE - albumin , Glob - globulin, MG-magnesium. 
Interpretation of biochemical results had as reference Ghergariu et al., (2000). 
Microbiology. Evaluation of changes in intestinal flora in dogs treated was made by 
comparing CFU/g faeces before and on third day of treatment. Were also isolated according to the 
procedures described by Queen (1994) the bacterial species eliminated in the feces after 3 days of 
treatment. Their sensitivity to erythromycin by disc diffusion method with microdisks of 
erythromycin (15 mg) according to Clinical and Laboratory Standards Institute , M31-A3 was also 
performed. Blood sampling for determination of haematological and biochemical parameters was 
done on day 0 and day 3 of the experiment for all individuals. Microbiological sampling to determine 
CFU/g faeces was performed at day 0 and day 3 of the experiment and samples for identification and 
susceptibility testing of fecal microorganisms was done on day 3 of the experiment. 
The results were statistically processed in Windows 7 enterprese by using the statistical 
program GraphPad Instant 3, calculating: 
-arithmetic mean and standard deviation; 
-statistical significance of differences ("t" test) between variants and groups respectively. 
Thresholds of significance "t" test were considered: p> 0.05 not significant, 0.01 <p 
<0.05 statistically significant (*), 0.001 <p <0.01 significantly distinct (**) and p <0.001 highly 
significant (***). 
 
RESULTS AND DISCUSSIONS 
 
As shown in Tab 1 between individual values and average parameters determined pre-
treatment and post-treatment in dogs of group A, we found statistically significant differences (p> 
0.05), after administration of 10% erythromycin in this animals category. 
Evolution of red cell parameters are recorded in Tab 1, where it can be seen that the 
mean values of hematocrit and hemoglobin ate in the physiological limits (37-55%, respectively 
12-18g/dl) in all groups. In group A hematrocrit increased post-treatment with an average of 
42.6%, while hemoglobin slightly decreased after treatment with an average of 15.89 g/dL. In 
case of total number of erythrocytes, mean values recorded were within physiological limits (6.81 
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 1.18 T/l ante therapeutic and 6.68  0.75 T/l after treatment), between the minimum of 5.62 T/l 
and maximum of 8.18 T/l. Mean erythrocyte constant levels showed less significant fluctuations 
than the mean reference values for this specie, for MEV (68.7 and -69.8 fl) for MEH (23.2 and 
23, 9 pg) MCHC showed similar values before and after treatment (32.76  2.03 pre-treatment 
and 33.06  1.01 g/dl post-treatment. 
In group B the average values of hematocrit and hemoglobin levels fall within 
physiological limits, hematrocrit and hemoglobin increased after treatment with an average of 
42.28% and respectively 15.39 g/dL after treatment. Total erythrocytes values are in the 
physiological limits for this specie with values of 8.33  1.0 T/l ante therapeutic and 8.01  1.12 
T/l after treatment. Mean erythrocyte constant levels showed significant fluctuations compared to 
average reference values but within phisiological limits for this specie. 
In control group C, average values were obtained at the beginning of the experiment and 
after the experiment of hematocrit were 38.9 to 37.90% falling within physiological limits (37.00 
to 55.00%) of the total number RBCs from 6.66 to 7.12 T/l, also normal values (5.5 to 8.5 t / l) 
and hemoglobin from 12.71 to 12.9 g/dL, corresponding to normal levels (12.0 to 18, 0 g/dl).  
Mean erythrocyte constants showed positive fluctuations at the end of the experiment: 
for MEV (65.3 fl and 67.7 fl postterapeutic) for MEH (22.30 to 22.34 pg) and for MCHC 32.17 - 




Mean eritrocytes values for the dog groups 
 
Group number 








Ht(%) 41.45±4.62 41±5.83 38.9±1.9 
Hb(g/dl) 16.01±1.95 15.39±1.59 12.71±1.7 
Eritrocyte nr.(T/l) 6.81±1.18 8.33±1 6.66±0.88 
Mean eritrocyte 
constants 
MEV/(fl) 68.7±3.65 66.6±4.66 65.3±3.91 
MEH (pg) 23.02±0.59 23.48±0.6 22.3±1.27 
MCHC(g/dl) 32.76±2.03 33.57±1.64 32.17±1.19 
Post-therapy/final 
Ht(%) 42.6±0.5 42.28±4.39 37.9±0.73 
Hb(g/dl) 15.89±0.8 15.18±1.85 12.9±1.22 
Nr.Eritrocite(T/l) 6.86±0.75 8.01±1.12 7.12±0.59 
Mean eritrocyte 
constants 
MEV/(fl) 69.8±5.94 69.4±4.93 67.7±5.43 
MEH (pg) 23.94±0.94 23.17±1.04 22.34±1.72 
MCHC(g/dl) 33.06±1.01 33.75±0.75 32.28±1.14 
 
Tab 2 presents individual and mean values of leukocyte parameters registered in dogs 
before and after clinical treatment with 10% erythromycin. In group A mean leukocyte 
parameters decreased after administration to 14.8 g / l after treatment from an average of 12, 
16g/l Neutrophils slightly decreased after treatment with erythromycin, from the initial average 
value of 62.4 ± 4.93 up to an average of 56.4 ± 12.07%, both values being within normal limits 
for dog. Average percentage levels of eosinophil did not exceed the upper limit of reference 
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(10.0%), being of 4.40% and 5.20%. Lymphocyte population showed minor variations of up to 
45.0%, with averages within physiological limits (from 12.0 to 30.0%). For monocytes averages 
obtained ante (10.6 ± 3.97%), and post-treatment (9.8 ± 2.59%), slightly increased but values did 
not exceeded physiological limits of the species (3 -10%). 
Leukocyte parameter values in group B showed significant changes after treatment. In 
case of neutrophils the values decreased after treatment with erythromycin 10%, from an initial of 
64.8 ± 3.63% to an average of 59.80 ± 2.17%, both values being included in normal values (60-
70%) but with significant differences between the two collections (p <0.05).  
Average percentage levels of eosinophil did not exceed the upper limit of reference 
(10.0%), being 5.8% anteterapeutic respectively 4.8% after treatment. Lymphocyte population 
showed significant variations between the two collections with an average of 22.20% ante and 
26.60% post therapeutic (p <0.05). For monocytes average values were within the normal values 
for this specie (3.0 to 10.0%). 
Evolution of leukocyte parameters in dogs from group C was characterized normal 
values both before and after the experiment. Total white blood count was 13.08 g/L initial and 
12.31 g/L at the end. In leukocyte formula, neutrophils represented the majority, with minimum 
41% and maximum 80%. Mean percentage of eosinophils were 5.60% and 4.6%, not exceeding 
upper reference limit of 10%. Lymphocytes average ranged between 20.2% and 25%, within the 
reference limits (12-30%), while monocytes were above the physiological limit, with levels 
between 8.4% and 8.6% which corresponded to a monocytosis both pre and post-treatment 




Mean leukocytes values for the dog groups 
 
Group number 








Leukocyte (G/l) 14.08±4.65 9.41±2.73 13.08±5.71 
Leukocytes 
formula (%) 
Neutrophyls 62.4±4.93 64.8±3.63 65.4±14.5 
Eosinophils 4.4±2.51 5.8±3.42 5.6±5.46 
Basophils 0.4±0.55 0.2±0.45 0.4±0.55 
Limphocytes 22.2±1.92 22.2±1.79 20.2±7.46 
Monocytes 10.6±3.97 7±3 8.4±3.85 
Post-therapy/final 
Leukocyte (G/l) 12.16±1.81 10.41±3.2 12.31±4.06 
Leukocytes 
formula (%) 
Neutrophyls 56.4±12.07 59.8±2.17** 61.2±12.32 
Eosinophils 5.2±1.64 4.8±1.1 4.6±2.97 
Basophils 0.4±0.55 0.4±0.55 0.6±0.55 
Limphocytes 28.2±9.65 26.6±3.21** 25±8.92 
Monocytes 9.8±2.59 8.4±1.14 8.6±2.61 
 
Tab 3 presents data specific to metabolic profile in dogs of group A with changes more or 
less important of the determined values. In case of albumin aslightly increased was observed after 
treatment, values in physiological limits for dog. For aspartate aminotransferase (8.9 to 49 U/l) the 
data obtained are within the limits physiological values. Glumatil gamma-transferase was constant 
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below 5 U/I. Total protein, globulin and urea nitrogen were within normal limits. Creatine 
phosphokinase was above the reference values both ante (154.8 ± 85U/L) and after treatment (131 
± 86.14 U/I). Calcium, magnesium and phosphorus were within the reference values. Only alkaline 
phosphatase in this group varied significantly between the two collections (p <0.05). 
In dogs of group B data are specific to the metabolic profile except for alkaline 
phosphatase - 98.2 ± 7.05 U/l initial and 101.4 ± 4.62 U/l at the end (p <0.05). 
In dogs of group C data are specific to the metabolic profile with all values within 
normal physiological limits, similar to Ghergariu et al., 2000. 
 
Tab 3.  
 
Mean biochemical parameters values for the dog groups 
 
Group number 
A B C 
Mean+ standard deviation Mean+ standard deviation Mean+ standard deviation 
Ante-therapy/before 
ALB (g/dl) 3.46±0.26 3.5±0.31 3.2±0.25 
ALP (U/l) 79.6±18.32 98.2±7.05 80±8.94 
AST (U/l) 35±4.3 39±4 32.2±6.06 
CA (mg/dl) 10.3±1.41 9.18±1.03 10.46±0.91 
TP (g/dl) 5.66±0.49 5.7±0.54 6.26±0.73 
GLOB (g/dl) 3.26±0.36 2.78±0.36 2.88±0.43 
BUN (mg/dl) 21.2±3.9 15±3 18.8±2.59 
CK (U/l) 154.8±85 118.6±17.42 107.4±13.9 
PHOS (mg/dl) 4.52±0.95 6.02±0.9 6.18±0.72 
MG (mg/dl) 2±0.22 1.94±0.19 2.16±0.18 
Post-therapy/final 
ALB (g/dl) 3.58±0.33 3.86±0.55 3.28±0.26 
ALP (U/l) 56.2±19.69* 101.4±4.62** 84.8±8.35 
AST (U/l) 37.8±3.42 41.4±2.07 34.4±1.82 
CA (mg/dl) 10.62±1.7 9.74±1.3 10.36±1.09 
TP (g/dl) 6.18±0.77 6.3±0.66 6.38±0.59 
GLOB (g/dl) 3.36±0.46 2.86±0.45 2.88±0.41 
BUN (mg/dl) 23.2±3.96 15±3.39 19±2.55 
CK (U/l) 131±86.14 108.6±24.91 111.2±16.15 
PHOS (mg/dl) 4.94±1.15 6.12±0.79 5.22±1.11 
MG (mg/dl) 2.1±0.35 2.04±0.29 2.1±0.14 
AST - aspartate aminotransferase, ALP - alkaline phosphatase, CK - creatine phosphokinase; 
CA - Calcium, PHOS - phosphorus, TP - total protein, GGT, gamma-glumatil transferase; 
BUN - blood urea nitrogen, WHITE - albumin, GLOB - globulin, MG-magnesium 
 
Changes of intestinal flora in terms of total germs number (NTG) in dog groups are 
shown in Tab 4, where a decrease of microorganisms in the groups treated with erythromycin is 
observed, dependent on the active substance concentration. Thus the three groups initially had a 
population with a number of intestinal microorganisms between 1.24x108 CFU/g and 1.33x108 
CFU/g. After the experiment in groups who received erythromycin the germs number decreased 
proportionally according to the concentration of substance (4.3x104 CFU/g in group A with 
1ml/10 kg and 1.2x102 CFU/g in group B with 2ml/10 Kg). Differences between the groups 
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treated with erythromycin and control group were significant (p <0.05). In control group (C) the 








A B C 
CFU/g Nr. CFU/g Nr. CFU/g Nr. 
Day 0 1.31x108 10 1.24x108 10 1.33x108 10 
Day 3 4.3x104 10 1.2x102 10 1.3x108 10 
 
The situation of bacterial strains resistance to erythromycin is present in tab 5. It is noted 
that out of 44 strains processed, most were classified as susceptible to the antibiotic. Thus all 
strains of Enterococcus spp were sensitive (100%). Different results were obtained by Ghosh et 
al., (2011) in a U.S. study on E. faecium where he obtained a resistance of 53.1% and E. faecalis 
with a 56.4% rate of resistance to erythromycin. Staphylococcus spp were sensitivie in 
percentage of 87.5%, those of E. coli and Proteus mirabilis of 73, 68% and 60%.  
Similar results were obtained by Rantala et al., (2004) in Finland observed that 
staphylococcus strains isolated from healthy dogs and dogs with pyoderma a resistance of 20%. 
For strains of E. coli and Enterococcus same authors found a small resistance, with no significant 
differences between groups with lesions and healthy dogs. In case of Pseudomonas aeruginosa 




Resistence to eritromycin of the bacterial strains isolated from the groups treated with eritromycin 
 

















spp. 0 1 7 8 0 12.5 87.5 
Enterococcus spp. 0 0 8 8 0 0 100 
Escherichia coli 1 4 14 19 5.26 21.05 73.68 
Proteus mirabilis 0 2 3 5 0 40 60 
Pseudomonas 





Our results argue that the administration of erythromycin therapeutic dose or double 
dose causes some significant changes in neutrophils, white blood cells and the alkaline 
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phosphatase in clinically healthy dogs. The effect of a quantitative reduction of intestinal flora is 
directly proportional to the amount of erythromycin administered. Erythromycin resistance was 
not detected in strains of Staphylococcus spp, Proteus spp Enterococcus spp. instead E. coli and 
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